HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture By Investing.com
” HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally ” ” Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business ” ” Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to … Read more